Opinion

Video

CAR T and Evolving Treatment Paradigms for Early R/R MM

Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.

Video content above is prompted by the following:

  • How has the use of CAR T evolved for patients with R/R multiple myeloma and what factors inform your practice?
  • Where does CAR T fall in your treatment paradigm? How does your approach differ with patients who are standard risk vs functional high risk?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
5 experts are featured in this series